In ALTA 1L trial, 275 patients with advanced ALK + (locally tested by Ventana IHC assay and/or FISH) NSCLC, who had not previously received ALK-I, were randomized to receive brigatinib or crizotinib [39]. This evidence concerns the gene ALK and non-small cell lung carcinoma.